Core Points - Lipocine Inc. has entered into a license, development, and supply agreement with SPC Korea for exclusive rights to market TLANDO® in South Korea [1][2] - The agreement includes an upfront payment, regulatory and sales milestone payments, and royalties on net commercial sales for Lipocine [2] - SPC Korea will be responsible for obtaining regulatory approval in South Korea [2] Company Overview - Lipocine is a biopharmaceutical company focused on enhancing therapeutics through effective oral delivery using its proprietary technology platform [5] - TLANDO is a testosterone replacement therapy approved by the US FDA for adult males with conditions related to endogenous testosterone deficiency [4][6] - The company is developing various drug candidates targeting significant unmet medical needs, including treatments for postpartum depression, epilepsy, essential tremor, chronic weight management, and liver cirrhosis [6]

Quantitative Electroencephalogram (qEEG) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (NAS), confirmed GABAA modulation Rapid and durable CNS target engagement confirms effective oral delivery of bioidentical brexanolone Promising results support continued development of oral brexanolone for the treatment of neuropsychiatric disorders SALT LAKE CITY, Oct. 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary ...

SALT LAKE CITY, Sept. 30, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present and meet with investors at the H.C. Wainwright 8th Annual MASH Investor Conference, to take place virtually on October 7, 2024. Presentation Details Time: 2:00 to 2:30pm ET Date: Monday, October 7, 2024 Webcast Link: https://journey.ct.events/view/c252f9f3-ea24-4af7 ...

Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek® conference to be held November 3 – ...

SALT LAKE CITY, Aug. 27, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that Dr. Mahesh V. Patel, President and Chief Executive Officer, will present and meet with investors at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024. Presentation Details Time: Available from 7:00 a.m. EDT onward ...

SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the second quarter ended June 30, 2024 and provided a corporate update. LPCN 1154 for Postpartum Depression (PPD) In June 2024, Lipocine announced positive topline study results from the NDA enabling study of LPCN 1154. LPCN 1154 treatment was well tolerated with no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended June 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ________. (Exact name of registrant as specified in its charter) Commission File Number: 001-36357 LIPOCINE INC. (Registrant's telephone number, including area code) ...

| --- | --- | --- | --- | |--------------|--------------------|--------------------|--------------------| | PK Parameter | GMR (%) | 90% CI LB | 90% CI UB | | | Test vs. Reference | Test vs. Reference | Test vs. Reference | | Cmax | 105 | 92 | 120 | | AUC0-∞ | 97 | 88 | 107 | | AUC0-t | 88 | 80 | 99 | LPCN 1154 treatment was well tolerated with no sedation nor somnolence events observed. All events were mild to moderate, and no severe or serious adverse events occurred. Reported study related events were ve ...

SALT LAKE CITY, June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Saturday, June 8, in Milan, Italy. The presentation "Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial" was presente ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock ali ...